Live flu vaccine trial
Friday, 27 February, 2009
Melbourne’s BioDiem and Schering-Plough’s vaccine business unit Nobilon have begun a clinical development program for BioDiem’s intranasal live attenuated influenza vaccine (LAIV).
The vaccine, named SCH 900795, is composed of three attenuated flu viruses that will be delivered in a single-dose intranasal spray.
The Phase I study will test the safety, tolerability and immunogenicity of the vaccine in 120 healthy volunteers.
Does exercise really extend lifespan? It's complicated
Physical activity is seen as a way to extend the human lifespan, but the benefits of physical...
Nature helps to relieve physical pain
Experiencing nature, even in the form of watching nature videos, can alleviate acute physical pain.
SEQ koala population carries immunity to retrovirus
Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...
